Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Cipla
Daiichi Sankyo
Julphar
Queensland Health
Novartis
Fish and Richardson
Boehringer Ingelheim
Teva

Generated: December 11, 2017

DrugPatentWatch Database Preview

NORDITROPIN FLEXPRO Drug Profile

« Back to Dashboard

When do Norditropin Flexpro patents expire, and what generic alternatives are available?

Norditropin Flexpro is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are twelve patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-one countries.

The generic ingredient in NORDITROPIN FLEXPRO is somatropin recombinant. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the somatropin recombinant profile page.

Summary for NORDITROPIN FLEXPRO

Drug patent expirations by year for NORDITROPIN FLEXPRO

Pharmacology for NORDITROPIN FLEXPRO

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010BXRXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010BXRXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010BXRXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NORDITROPIN FLEXPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010► Subscribe► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NORDITROPIN FLEXPRO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,357,120Injection device with torsion spring and rotatable display► Subscribe
7,686,786Dial-down mechanism for wind-up pen► Subscribe
9,616,180Automatic injection device with a top release mechanism► Subscribe
8,096,978Automatic injection device with a top release mechanism► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NORDITROPIN FLEXPRO

Country Document Number Estimated Expiration
European Patent Office1804865► Subscribe
European Patent Office1877119► Subscribe
Poland329386► Subscribe
Denmark1843809► Subscribe
South Africa200703707► Subscribe
Spain2394556► Subscribe
Austria445430► Subscribe
Canada2595323► Subscribe
Japan5340603► Subscribe
European Patent Office0904099► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
US Department of Justice
US Army
Medtronic
Merck
AstraZeneca
Fish and Richardson
Teva
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot